Chapter 1: Overview: B. Burtness and E. Golemis
Chapter 2: HER inhibition in HNC: E. Golemis and B. Burtness
Chapter 3: MET: T Beck, Fox Chase Cancer Center
Chapter 4: PI3K/mTOR/AMPK: C. Chung, Moffit Cancer Center
Chapter 5: Jak/STAT: J.R. Grandis, UCSF
Chapter 6: TGFb: Neiman and Wang, University of ColoradoChapter 7: Wnt and catenin Signaling: MA Kukurusinska, Boston University
Chapter 8: P53/p63/p73: B. Burtness
Chapter 9: DNA damage: R. Bindra, Yale University
Chapter 10: APOBEC Proteins: K.S. Anderson, Yale University
Chapter 11: Hypoxia, including HIF1: Q. Le, Stanford UniversityChapter 12: VEGF/Angiogenesis and Antiangiogenic Therapy: A Argiris, Thomas Jefferson University
Chapter 13: Sequencing/genomic insights: J.Myers, MD Anderson
Chapter 14: Gene expression, Methylation, and histones: R.Mehra, A.Andrews, S.Peri, Fox Chase Cancer Center and A.Bhatia, Yale University
Chapter 15: Inflammation: Carter Van Waes, NIH
Chapter 16: Immunotherapy: Ferris and Baumann, UPMC
Chapter 17: FAK/Integrin pathway inhibitors: Nils Cordes, Dresden
Chapter 18: Targeting cell cycle controls: E.Golemis
Chapter 19: Head and neck cancer stem cells: L.Bourguignon, UCSF
Chapter 20: Non-coding RNAs: C.Punyadeera, Queensland University
Chapter 21: Epidemiology of HPV: Ragin and Lui, Fox Chase Cancer Center
Chapter 22: DNA damage in HPV-positive SCCHN: WG Yarbrough, Yale UniversityChapter 23: Treatment paradigms in HPV-positive SCCHN: A Cmelak, Vanderbilt University
About the Author:
Barbara Burtness, M.D. is Professor of Medicine, Yale University School of Medicine and Co-Leader, Developmental Therapeutics Program, Yale Cancer Center. As Chair of the Head and Neck Committee in Eastern Cooperative Oncology Group and a member of the NCI Head and Neck Steering Committee, she helps shape the national agenda for research on all stages of head and neck cancer.
Erica Golemis, Ph.D. is the Deputy Chief Scientific Officer and Co-leader of the Program in Molecular Therapeutics at the Fox Chase Cancer Center. Her research seeks to define the changes in cell signaling that occur as tumors spread by metastasis and develop resistance to drugs, with the ultimate goal of inhibiting these processes to effect disease control and cure.
